From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts William Gradishar, MD, FASCO, FACP; and Kamel Abou Hussein, MD; discuss optimizing first-line treatment selection in metastatic triple-negative breast cancer (TNBC) with emerging antibody-drug conjugates (ADCs) and biomarker-guided strategies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate recent data from clinical trials to assess the role of ADCs in the frontline treatment of metastatic TNBC
• Implement novel frontline treatment options for patients with metastatic TNBC across biomarker subgroups, including PD-L1–positive, PD-L1–negative, and IO-ineligible
• Implement treatment sequencing approaches for patients with metastatic TNBC across the disease continuum

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Faculty:

William J. Gradishar, MD, FASCO, FACP

Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Chief, Division of Hematology/Oncology
Feinberg School of Medicine at Northwestern University
Chicago, IL

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Celcuity, Genentech, Lilly, Pfizer, Roche, Stemline

Kamel Abou Hussein, MD

Assistant Professor of Medicine
Cooper Medical School of Rowan University
MD Anderson Cancer Center at Cooper
Camden, NJ

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca; Speakers Bureau: Lilly

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on including information on biomarker testing, PARP inhibitors, and emerging ADCs in metastatic TNBC, go to https://www.gotoper.com/courses/from-trials-to-the-clinic-incorporating-new-advances-in-metastatic-tnbc

Release Date

August 3, 2026

Expiration Date

August 3, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.